TechnoVax Receives $2.9M Grant for Flu and Influenza Virus-Like Particle Vaccine Program

TechnoVax, Inc., a biotechnology developer of novel vaccines, was awarded a three-year $2.9m SBIR phase II grant from the National Institutes of Health to further the development of its Virus-Like Particle (VLP)-based, vaccine program.
As stated by Dr. Jose Galarza, CEO of TechnoVax, “This award and recognition from the NIH emphasizes the importance of the VLP technology and this support will allow us to complete preclinical development and move into clinical testing of our influenza VLP vaccine candidates, including our H1N1 swine flu vaccine”.
The Westchester County, New York-based company, which uses its unique and innovative VLP technology to produce mass market vaccines for infectious diseases such as influenza, respiratory syncytial virus (RSV), para-influenza virus (PIV) and other diseases such as HIV and cancer, aims to begin clinical trials within the next 18 months.

Join the discussion